Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Status of Circulating Tumor DNA and Its Impact on Adjuvant Chemotherapy Following Resection of Colorectal Liver Metastases

  • By

  • Kozo Kataoka

  • Kazuma Ito

  • Yoshiaki Nakamura

  • Jun Watanabe

  • Naoya Akazawa

  • Jun Nagata

  • Mitsuru Yokota

  • Kentaro Kato

  • Masahito Kotaka

  • Tadayoshi Hashimoto

  • Kentaro Yamazaki

  • Yoshinori Kagawa

  • Saori Mishima

  • Koji Ando

  • Masaaki Miyo

  • Hiroki Yukami

  • Arkarachai Fungtammasan

  • Shruti Sharma

  • J. Bryce Ortiz

  • Matthew Rabinowitz

  • Robert W. Lentz

  • Adham Jurdi

  • Minetta C. Liu

  • Alexey Aleshin

  • Daisuke Kotani

  • Hideaki Bando

  • Hiroya Taniguchi

  • Ichiro Takemasa

  • Takeshi Kato

  • Takayuki Yoshino

  • Eiji Oki

  • CIRCULATE-Japan Group

  • Kei Kimura

  • Ikuo Matsuda

  • Masataka Ikeda

  • Yuko Fukumoto

  • Satoshi Kobayashi

  • Hiroki Sokuoka

  • September 1, 2026

Share

  • 1

    Colorectal liver metastasis (CRLM) significantly contributes to cancer-related mortality, with recurrence affecting up to two-thirds of patients post-surgery.

  • 2

    Circulating tumor DNA (ctDNA) is a promising biomarker for identifying molecular residual disease and predicting recurrence risk in colorectal cancer.

  • 3

    The CIRCULATE-Japan GALAXY study evaluates ctDNA status in stage II–IV colorectal cancer patients undergoing curative resection.

  • 4

    This analysis included 298 patients with resected CRLM, comparing outcomes between those who underwent upfront surgery and those who received neoadjuvant chemotherapy.

  • 5

    The study found that adjuvant chemotherapy (ACT) improved disease-free survival in patients with ctDNA positivity, but its effect on overall survival remains uncertain.

Original Source(s)

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

  • by Kozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Jun Nagata, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Tadayoshi Hashimoto, Kentaro Yamazaki, Yoshinori Kagawa, Saori Mishima, Koji Ando, Masaaki Miyo, Hiroki Yukami, Arkarachai Fungtammasan, Shruti Sharma, J. Bryce Ortiz, Matthew Rabinowitz, Robert W. Lentz, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki, CIRCULATE-Japan Group, Kei Kimura, Ikuo Matsuda, Masataka Ikeda, Yuko Fukumoto, Satoshi Kobayashi, Hiroki Sokuoka

  • September 1, 2026

Related Content

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min
Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling